



Government of the People's Republic of Bangladesh
Directorate General of Drug Administration
Mohakhali, Dhaka-1212, Bangladesh
www.dgda.gov.bd

Memo no. DGDA/COVID-19 vac/PV/2020/09

Dated: 25 January 2021

Subject : Formation of Pharmacovigilance & COVID-19 Safety Surveillance Cell at DGDA

Health Services Division, Ministry of Health and family Welfare formed the 'Quality Assurance Committee for ensuring quality, safety and efficacy of COVID-19 vaccine' vide letter no 45.00.0000.182.06.012.08-15. Dated 14.12. 2020. The committee prepared the the Pharmacovigilance Protocol for COVID-19 vaccines which has been approved by the MoHFW.

In the light of the approved protocol a Pharmacovigilance and COVID-19 Safety Surveillance Cell is formed as under:

S.N	Name, Designation, Institution	Mobile Number & e-mail	Committee
1.	Dr. Md. Akter Hossain Deputy Director, DGDA	01711071010 akterh4@gmail.com	Head of Pharmacovigilance & COVID-19 Safety Surveillance Cell
2.	Dr. Nusrat Akhter Jahan Medical Officer, DGDA	01813019276 nusratdgda@gmail.com	Member
3.	Expert Representative from EPI Dr. Md. Tanvir Hossen, DPM-EPI	01717572284 tanvirantik@gmail.com	Member
4.	Expert Representative from IEDCR Dr. Mallick Masum Billah, FETPB Advisor, IEDCR	01312496597 drmasumbillah@yahoo.com	Member
5.	Consultant, WHO		Member
6.	Experts from USAID MTaPS Md. Abul Kalam Azad	01794285926 mazad@mtapsprogram.org	Member
7.	Experts from USP-PQM+		Member
8.	Clinician (Internal medicine specialist- Dermatologist/Infectious Disease specialist)		Member
9.	Biostatistician		Member
10.	IT Experts:		
	A. N. M Arshadul Mortuza (WHO)	01313700638 arahadulm@gmail.com	Member
	Md. Lutful Haque Protik (USAID MTaPS)	01711180555 mlhaque@mtapsprogram.org	Member
11.	Gulshan Jahan, Assistant Director, DGDA	01711950490 gjriima@yahoo.com	Member Secretary

Note: The cell may co-opt any expert as member if required.

TOR of the committee:

- Compilation of AEFI reports, investigation reports and other documents.
- Coordination with different committees as regular follow up and updates.
- The cell will provide secretarial support to the National AEFI Expert Review Committee.
- Literature review for collecting AEFI related global information.

২

৪

৫

৬



- Maintain data management of vaccine safety surveillance with DGDA.
- Data sharing to WHO-UMC Vigiflow.
- Assist DGDA in the communication and implementation of regulatory decisions regarding AEFI issues.

Coordinate with National Vaccine Deployment Program, Expanded Program on Immunization (EPI) and other relevant stakeholders


Major General Md Mahbubur Rahman
Director General

Directorate General of Drug Administration (DGDA)

Phone: 022222-80803

e-mail: dgda.gov@gmail.com

Distributions (not according to the seniority):

1. Dr. Md. Akter Hossain, Deputy Director, DGDA
2. Dr. Nusrat Akhter Jahan, Medical Officer, DGDA
3. Dr. Md. Tanvir Hossen, Deputy Program Manager- EPI and Surveillance
4. Dr. Mallick Masum Billah, Senior Advisor, IEDCR
5. Md. Abul Kalam Azad, Senior Technical Advisor, USAID-MTaPS
6. Experts from USP-PQM+
7. Clinician
8. Biostatistician
9. A. N. M Arshadul Mortuza (WHO)
10. Md. Lutful Haque Protik (USAID MTaPS)
11. Gulshan Jahan, Assistant Director, DGDA

Memo no. DGDA/COVID-19 vac/PV/2020/

Dated: 25 January 2021

Copy for kind information and necessary actions (not according to the seniority)

1. Secretary, Health Division, Ministry of Health and Family welfare, Bangladesh Secretariat.
2. Director General, DGHS, Mohakhali, Dhaka.
3. Additional Secretary, Drug Administration wing, MoHFW
4. Additional Director General (Admin), DGHS, Mohakhali, Dhaka.
5. Director and Line Director MNC&AH (EPI)
6. Director General (Hospital), DGHS, Mohakhali, Dhaka.
7. Personal secretary to the Minister, MoHFW.
8. WHO Representative to Bangladesh, Country office, Gulshan-1, Dhaka.


Director General
Directorate General of Drug Administration (DGDA)

25 JAN 2021